关注
Guido Moll
标题
引用次数
引用次数
年份
Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long‐term engraftment and no ectopic tissue formation
L Von Bahr, I Batsis, G Moll, M Hägg, A Szakos, B Sundberg, M Uzunel, ...
Stem cells 30 (7), 1575-1578, 2012
5982012
Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?
G Moll, JJ Alm, LC Davies, L von Bahr, N Heldring, L Stenbeck-Funke, ...
Stem cells 32 (9), 2430-2442, 2014
3782014
Are therapeutic human mesenchymal stromal cells compatible with human blood?
G Moll, I Rasmusson-Duprez, L von Bahr, AM Connolly-Andersen, ...
Stem cells 30 (7), 1565-1574, 2012
3612012
Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements
J Doorn, G Moll, K Le Blanc, C Van Blitterswijk, J de Boer
Tissue Engineering Part B: Reviews 18 (2), 101-115, 2012
3542012
Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines
G Moll, JA Ankrum, J Kamhieh-Milz, K Bieback, O Ringdén, HD Volk, ...
Trends in molecular medicine 25 (2), 149-163, 2019
3392019
Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application
H Caplan, SD Olson, A Kumar, M George, KS Prabhakara, P Wenzel, ...
Frontiers in immunology 10, 1645, 2019
2382019
Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses
G Moll, R Jitschin, L von Bahr, I Rasmusson-Duprez, B Sundberg, ...
PloS one 6 (7), e21703, 2011
1762011
Galectin-1 mediated suppression of Epstein-Barr virus–specific T-cell immunity in classic Hodgkin lymphoma
MK Gandhi, G Moll, C Smith, U Dua, E Lambley, O Ramuz, D Gill, ...
Blood, The Journal of the American Society of Hematology 110 (4), 1326-1329, 2007
1762007
MSC therapies for COVID-19: importance of patient coagulopathy, thromboprophylaxis, cell product quality and mode of delivery for treatment safety and efficacy
G Moll, N Drzeniek, J Kamhieh-Milz, S Geissler, HD Volk, P Reinke
Frontiers in immunology 11, 1091, 2020
1612020
Cryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy?
G Moll, S Geißler, R Catar, L Ignatowicz, MJ Hoogduijn, D Strunk, ...
Biobanking and Cryopreservation of Stem Cells 951, 77-98, 2016
1602016
Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial
A Roemhild, NM Otto, G Moll, M Abou-El-Enein, D Kaiser, G Bold, ...
bmj 371, 2020
1462020
Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua
G Moll, L Ignatowicz, R Catar, C Luecht, B Sadeghi, O Hamad, ...
Stem cells and development 24 (19), 2269-2279, 2015
1212015
Crimean-Congo hemorrhagic fever virus activates endothelial cells
AM Connolly-Andersen, G Moll, C Andersson, S Åkerström, H Karlberg, ...
Journal of virology 85 (15), 7766-7774, 2011
1092011
Improved MSC minimal criteria to maximize patient safety: a call to embrace tissue factor and hemocompatibility assessment of MSC products
G Moll, JA Ankrum, SD Olson, JA Nolta
Stem cells translational medicine 11 (1), 2-13, 2022
962022
Alterations in the cellular immune compartment of patients treated with third‐party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation
R Jitschin, D Mougiakakos, L Von Bahr, S Völkl, G Moll, O Ringden, ...
Stem Cells 31 (8), 1715-1725, 2013
952013
Placenta-derived decidua stromal cells for treatment of severe acute graft-versus-host disease
O Ringden, A Baygan, M Remberger, B Gustafsson, J Winiarski, B Khoein, ...
Stem Cells Translational Medicine 7 (4), 325-331, 2018
932018
Editorial: Safety, Efficacy and Mechanism of Action of Mesenchymal Stem Cell Therapies
G Moll, MJ Hoogduijn, JA Ankrum
Frontiers in Immunology 11, 243, 2020
872020
Multi-Parameter Analysis of Biobanked Human Bone Marrow Stromal Cells Shows Little Influence for Donor Age and Mild Comorbidities on Phenotypic and Functional Properties.
A Andrzejewska, R Catar, J Schoon, TH Qazi, FA Sass, D Jacobi, ...
Frontiers in Immunology 10 (2474), 1-24, 2019
802019
Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells?
G Moll, A Hult, L Bahr, JJ Alm, N Heldring, OA Hamad, L Stenbeck-Funke, ...
PLoS one 9 (1), e85040, 2014
792014
Impact of cryopreservation and freeze-thawing on therapeutic properties of mesenchymal stromal/stem cells and other common cellular therapeutics
C Cottle, AP Porter, A Lipat, C Turner-Lyles, J Nguyen, G Moll, ...
Current stem cell reports 8 (2), 72-92, 2022
772022
系统目前无法执行此操作,请稍后再试。
文章 1–20